Skip to main content
Retour
Watch Compare

Tempest Therapeutics, Inc.

Qualité des données : 83%
TPST
NASDAQ Manufacturing Chemicals
2,24 €
▲ 0,12 € (5,66%)
6 months return
—
Momentum
Neutral
ROE
-325,65%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-325,65%
En dessous de la moyenne du secteur (-54,68%)
ROIC-135,68%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio2,30
Interest Coverage-128,38

Valorisation

PE (TTM|NTM)
-0,85 | -1,75
Au-dessus de la moyenne du secteur (-1,49)
P/B Ratio3,53
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -26,82 M

Price History

Tendances Financières

Objectif de Cours des Analystes

1 analyste
Buy
+391.1%
upside to target
Actuel
2,24 €
Consensus Target
11,00 €
11,00 €
Bas
11,00 €
Haut
Prévisions
P/E Prévisionnel
-1,75
BPA Prévisionnel
-1,21 €
CA Est.
0,0

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -0,28 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -3,16 € -2,07 € -0,79 € -0,62 € — —
Estimate -3,29 € -3,23 € -3,27 € -0,62 € -0,28 € -0,30 €
Surprise +4,05% +35,91% +75,84% 0,00% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -325,65% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -26,26 M
ROE -325,65% ROA -126,22%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -26,82 M
ROIC -135,68% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,30
Debt / Equity N/A Current Ratio 2,30
Interest Coverage -128,38 Asset Turnover N/A
Working Capital 4,58 M Tangible Book Value 6,35 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,85 · EV/EBITDA: N/A
P/E Ratio -0,85 Forward P/E -1,75
P/B Ratio 3,53 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -119,86%
Market Cap 22,38 M Enterprise Value 14,86 M

Per Share

EPS: -6,33 · FCF/Share: -1,87
EPS (Diluted TTM) -6,33 Revenue / Share N/A
FCF / Share -1,87 OCF / Share -1,87
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 102,12% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 102,12%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -26,26 M -41,84 M -29,49 M -35,71 M -28,30 M
EPS (Diluted) -6,33 -1,50 -1,91 -3,09 -7,47
Gross Profit — — — — —
Operating Income -26,58 M -42,03 M -29,16 M -34,64 M -26,99 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 207 000,0 1,32 M 1,45 M 1,62 M 1,28 M
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,93 M 41,49 M 51,60 M 46,09 M 73,24 M
Total Liabilities 10,26 M 22,36 M 24,84 M 27,98 M 37,12 M
Shareholders' Equity 6,67 M 19,13 M 26,77 M 18,11 M 36,12 M
Total Debt — 6,40 M 10,50 M 10,40 M 15,07 M
Cash & Equivalents 7,71 M 30,27 M 39,23 M 31,23 M 51,83 M
Current Assets 8,27 M 31,47 M 40,36 M 32,95 M 68,96 M
Current Liabilities 3,31 M 14,22 M 9,41 M 7,28 M 20,03 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,9 -1,5
P/B 3,5 1,6
ROE % -325,7 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3